Septerna SEPN 深 沪
等待开盘 09-04 09:30:00 美东时间
36.80
-0.700
-1.87%
华盛通- 最 高38.195
- 今 开37.72
- 成交量 24.16万股
- 最 低 36.46
- 昨 收 37.50
- 总市值 17.18亿
- 52周最高 51.10
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 14.00
- 委 比 -90.48%
- 总股本 4667.69万
- 历史最高 51.10
- 量 比 0.76
- 振 幅 4.63%
- 历史最低 4.17
- 每 手 1
- 风险率 6.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Septerna Appoints Rajiv Patni as Chief Medical Officer
An announcement from Septerna, Inc. ( ($SEPN) ) is now available. Septerna, Inc...
08-25 20:47
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Septerna, Inc. has appointed Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni, with over 25 years of experience in biopharmaceuticals, will lead the company's clinical development efforts targeting GPCRs. His expertise will support Septerna's mission to develop innovative oral therapies for unmet medical needs across endocrinology, immunology, and other areas. Septerna's Native Complex Platform® enables novel GPCR drug discovery, advancing ...
08-25 12:00
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from $38 to $48.
08-20 02:47
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股牛股 | 绩优股普升！量子计算股昆腾飙升64%，NIQ劲升42%
绩优股普升！量子计算公司昆腾飙升64%，近三年来首度非GAAP单季盈利；NIQ劲升42%，Q2 EPS扭亏大幅增长；Fermi升逾21%，签署大规模AI数据中心长期租约>>
08-12 15:54
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Guggenheim Maintains Buy on Septerna, Raises Price Target to $51
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $45 to $51.
08-11 22:20
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Septerna, Inc. reported progress on its Phase 1 clinical trial for SEP-479, a PTH1R agonist for hypoparathyroidism, with pharmacokinetic data supporting once-daily dosing. The company expects to present SAD/MAD data in Q1 2027. SEP-631, an MRGPRX2 NAM for mast cell-driven diseases, is advancing with plans for capital-efficient studies. The TSHR NAM program is progressing toward development candidate selection. Septerna's cash position of $516.5 m...
08-10 20:01
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Tuesday. Shares of DigitalOcean Holdings Inc (NYSE:DOCN) rose sharply after the company announced it expects a year-over-year increase in second-quarter revenue growth results. Also, the company expects to be at or above the top ...
07-07 22:00
